cu 64 m5a
mAbexperimentalADC
Clinical trial activity
2 trials · 2 clinical orgs · 0 marketing orgs
Phase 1
1
Phase 2
0
Phase 3
0
Phase 4
0
Earliest trial started Jun 8, 2015 (NCT02293954)
Timeline
2020s
- Jan 1, 2022
Earliest Phase 1 Sponsor(trial)
Indications
Studied for
Mechanism of action
- Carcinoembryonic antigen-related cell adhesion molecule 5Immunity, passive
CEACAM5 immunity, passive
Chemistry & pharmacology
- Multi-specific
- No
- Payload
- 64-copper
Oral
No
Parenteral
No
Topical
No
Also known as
- cu 64 m5a
Clinical trials
| NCT ID | Phase | Start date | Sponsor(s) |
|---|---|---|---|
| NCT05245786 | Early Phase 1 (Phase 1) | Aug 31, 2022 | City of Hope National Medical Center, National Cancer Institute (NCI) |
| NCT02293954 | N/A | Jun 8, 2015 | City of Hope National Medical Center, National Cancer Institute (NCI) |
Showing 2 of 2 trials
Page 1 / 1
Organizations
Research & Development (2)
| Organization | Org type | Trials | As lead sponsor | Phases | Earliest year |
|---|---|---|---|---|---|
| City of Hope National Medical Center | Academic/Hospital | 2 | 2 | 2 | 2015 |
| National Cancer Institute (NCI) | Government | 2 | 0 | 2 | 2015 |
2 organizations
Page 1 / 1